Clinical Trial Update: Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating stereotactic body radiation therapy combined with an anti-PD-1 antibody in metastatic triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Anti-PD-1 antibody

Snippet

Sponsor: Fudan University | Conditions: Metastatic Breast Cancer | Phase 1 | Status: UNKNOWN